Quantitative metabolomics services for biomarker discovery and validation.
Specializing in ready to use metabolomics kits.
Your source for quantitative metabolomics technologies and bioinformatics.
Loader

Filter by Pathway Type:



Showing 161 - 170 of 605359 pathways
SMPDB ID Pathway Name and Description Pathway Class Chemical Compounds Proteins

SMP0174640

Pw176315 View Pathway

Acrivastine Predicted Metabolism Pathway

Metabolites of sildenafil are predicted with biotransformer.
Metabolic
  • Acrivastine
  • Acrivastine PIS1M1
  • Acrivastine PIS1M2
  • Acrivastine PIS2M1
  • Heme

SMP0128680

Pw130299 View Pathway

Acrothecium robustum Drug Metabolism

Metabolic

SMP0130520

Pw132188 View Pathway

Activated charcoal Drug Metabolism

Activated charcoal is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Activated charcoal passes through the liver and is then excreted from the body mainly through the kidney.
Metabolic
  • Activated charcoal

SMP0144399

Pw146067 View Pathway

Activated charcoal Drug Metabolism Action Pathway

Drug Action
  • Activated charcoal

SMP0063764

Pw064756 View Pathway

Activation of cAMP-dependent protein kinase, PKA

cAMP dependent protein kinase is a signalling molecule, found in the nucleus and cytoplasm of cells. Cellular regulation and signal transduction in eukaryotic cells is driven by the phosphorylation of proteins. cAMP dependent protein kinase is created as an active enzyme, which is made possible by a fully phosphorylated activation loop.
Protein

SMP0000749

Pw000726 View Pathway

Activation of PKC Through G Protein-Coupled Receptor

G protein-coupled receptors sense stimuli outside the cell and transmit signals across the plasma membrane. Activation of protein kinase C (PKC) is one of the common signaling pathways. When a class of GPCRs are activated by a ligand, they activate Gq protein to bind GTP instead of GDP. After the Gq becomes active, it activates phospholipase C (PLC) to cleave the membrane lipid phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacyl glycerol (DAG). IP3 can bind Ins3P receptor to open calcium channel by diffusion from cytoplasm to ER. Activated calcium channel will release the calcium from ER into cytoplasm. Calcium can activate the kinase activity of PKC.
Signaling

SMP0130184

Pw131803 View Pathway

Actoxumab Drug Metabolism

Metabolic

SMP0000344

Pw000174 View Pathway

Acute Intermittent Porphyria

Acute intermittent porphyria (AIP), also called Swedish porphyria, is a rare inborn error of metabolism (IEM) and autosomal dominant disorder of heme biosynthesis caused by a defective HMBS gene. The HMBS gene codes for the protein hydroxymethylbilane synthase (porphobilinogen deaminase) which catalyzes the synthesis of porphobilinogen into hydroxymethylbilane. This disorder is characterized by a large accumulation of 5-aminolevulinic acid or porphobilinogen in both urine and serum. Most patients are asymptomatic between attacks. Symptoms of the disorder include abdominal pain, constipation, vomiting, hypertension, muscle weakness, seizures, delirium, coma, and depression. Treatment involves undertaking a high-carbohydrate diet and, during severe attacks, a glucose 10% infusion. It is estimated that AIP affects 5.9 per 1 000 000 people.
Disease

SMP0125644

Pw127208 View Pathway

Acute Intermittent Porphyria

Acute intermittent porphyria (AIP), also called Swedish porphyria, is a rare inborn error of metabolism (IEM) and autosomal dominant disorder of heme biosynthesis caused by a defective HMBS gene. The HMBS gene codes for the protein hydroxymethylbilane synthase (porphobilinogen deaminase) which catalyzes the synthesis of porphobilinogen into hydroxymethylbilane. This disorder is characterized by a large accumulation of 5-aminolevulinic acid or porphobilinogen in both urine and serum. Most patients are asymptomatic between attacks. Symptoms of the disorder include abdominal pain, constipation, vomiting, hypertension, muscle weakness, seizures, delirium, coma, and depression. Treatment involves undertaking a high-carbohydrate diet and, during severe attacks, a glucose 10% infusion. It is estimated that AIP affects 5.9 per 1 000 000 people.
Disease

SMP0128033

Pw129652 View Pathway

ACY001 Drug Metabolism

Metabolic
Showing 161 - 170 of 65006 pathways